Saccadic Analysis for Early Identification of Neurological Involvement in Gaucher Disease
Overview
Authors
Affiliations
The early identification of a neurological involvement in Gaucher's Disease (GD) is essential for a correct dosage of the enzymatic therapy. The saccadic eye movement characteristics of 15 patients affected by the non-neurological GD form show normal peak velocity values and some slight alterations of the velocity profiles present in more than 70% of the recorded eye movements in four cases; two of them later developed epilepsy. This fact supports the hypothesis that the presence of alterations in the velocity profile of the most part of saccadic movements is an index of initial neurological involvement. Further evaluations are necessary in order to understand if an increase of therapy dose should be used in all the subjects presenting such saccadic alterations.
A review of type 3 Gaucher disease: unique neurological manifestations and advances in treatment.
Zhong W, Li D, Fei Y, Hong P Acta Neurol Belg. 2024; 124(4):1213-1223.
PMID: 38413480 DOI: 10.1007/s13760-024-02493-1.
Hopf S, Pfeiffer N, Liesenfeld M, Mengel K, Hennermann J, Schmidtmann I Orphanet J Rare Dis. 2019; 14(1):257.
PMID: 31727115 PMC: 6857165. DOI: 10.1186/s13023-019-1244-9.
Basic and translational neuro-ophthalmology of visually guided saccades: disorders of velocity.
Puri S, Shaikh A Expert Rev Ophthalmol. 2019; 12(6):457-473.
PMID: 30774705 PMC: 6377082. DOI: 10.1080/17469899.2017.1395695.
Eye movement disorders and neurological symptoms in late-onset inborn errors of metabolism.
Koens L, Tijssen M, Lange F, Wolffenbuttel B, Rufa A, Zee D Mov Disord. 2018; 33(12):1844-1856.
PMID: 30485556 PMC: 6587951. DOI: 10.1002/mds.27484.
Eye movement impairment recovery in a Gaucher patient treated with miglustat.
Accardo A, Pensiero S, Ciana G, Parentin F, Bembi B Neurol Res Int. 2010; 2010:358534.
PMID: 21152212 PMC: 2989716. DOI: 10.1155/2010/358534.